Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

• Drug: AAB-003 (PF-05236812)
  
  0.5 mg/kg AAB-003, IV
• Drug: AAB-003 (PF-05236812)
  
  1 mg/kg AAB-003, IV
• Drug: AAB-003 (PF-05236812)
  
  2 mg/kg AAB-003, IV
• Drug: AAB-003 (PF-05236812)
  
  4 mg/kg AAB-003, IV
• Drug: AAB-003 (PF-05236812)
  
  8 mg/kg AAB-003, IV
• Other: Placebo
  
  Placebo, IV

• Experimental: 0.5 mg/kg AAB-003
  
  Intervention: Drug: AAB-003 (PF-05236812)
• Experimental: 1 mg/kg AAB-003
  
  Intervention: Drug: AAB-003 (PF-05236812)
• Experimental: 2 mg/kg AAB-003
  
  Intervention: Drug: AAB-003 (PF-05236812)
• Experimental: 4 mg/kg AAB-003
  
  Intervention: Drug: AAB-003 (PF-05236812)
• Experimental: 8 mg/kg AAB-003
  
  Intervention: Drug: AAB-003 (PF-05236812)
• Placebo Comparator: Placebo
  
  Intervention: Other: Placebo

Inclusion Criteria:

• Diagnosis of probable Alzheimer's Disease with MMSE score of 16-26, and brain MRI consistent with the diagnosis of Alzheimer's Disease
• Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
• Caregiver will participate and be able to attend clinic visits with patient

Exclusion Criteria:

• Significant neurological disease other than Alzheimer's Disease
• Major psychiatric disorder
• Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
• Women of childbearing potential